Can AbbVie's Legacy Products Deliver Further Growth? Motley Fool ... death) being studied in hematologic malignancies, including chronic lymphocytic leukemia; and an experimental new drug treatment offering multifactorial immunomodulatory effects for people with relapsing, remitting multiple sclerosis, called ... |
